Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney

The Cambridge, Massachusetts-based biotech is using what it calls ligand-siRNA conjugates to reach drug targets in the kidney, which historically have been difficult to reach with RNA therapies.